Correct. And though the data is considered anecdotal, that’s in relation to potential approval where blinded trials are generally required. In real life, outside of regulatory pathways, it’s showing it’s value and that doesn’t go unnoticed. But don’t forget (pointing at Hulk here) that it was mentioned numerous times on calls that the data so far was very strong. This was essentially confirmed by the fact the PH ordered more. They wouldn’t do that for no reason. Even if this effort doesn’t currently give us strong enough footing for an EUA there, it’s a real world application of LL that will pay off in other ways. Or later when we have a little more to share with the PH from Brazil.